ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN: L24110TG1986PLC006885

Date: 12-02-2025

To

1. BSE Limited, P.J. Towers, Dalal Street, Mumbai-400001 **Scrip code: 539287**	2. National Stock Exchange of India Limited, Exchange Plaza, Bandra- Kurla Complex, Mumbai-400051 **Symbol: ORTINGLOBE**

Sub: Outcome of Board Meeting held on 12-02-2025

Dear Sir/Madam,

With reference to the above mentioned subject, this is to inform the Exchanges that the Board of Directors of Ortin Global Limited (Formerly Known as Ortin Laboratories Limited) at its meeting held on Wednesday, 12-02-2025 at 4:00 p.m. at the Registered Office of the Company inter-alia considered and approved the following:

1. Un-audited Financial Results of the company along with Limited Review Report for the quarter ended 31-12-2024. (Enclosed as Annexure)

The Meeting Concluded at 06.30 pm

We request you to take note of the same in your records.

Thanking you.

Yours sincerely,
For Ortin Global Limited
(formerly known as Ortin Laboratories Limited)

MURALI KRISHNA MURTHY SANKA
Digitally signed by MURALI KRISHNA MURTHY SANKA
Date: 2025.02.12 18:32:43 +05'30'

S. Murali Krishna Murthy
Managing Director
DIN: 00540632

Encl: as mentioned above:

Regd. Office: **Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India**.
Email:info@ortinlabsindia.com **Website:www.ortinlabsindia.com**
Ph. No. +91 9052011118

MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on unaudited quarterly and year to date financial results of the Company

To The Board of Directors of Ortin Global Limited (Formerly known as Ortin Laboratories Limited)

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Global Limited (Formerly known as Ortin Laboratories Limited) ("the Company") for the quarter ended on 31st December, 2024 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

MATHESH & RAMANA FRN: 002020S HYDERABAD CHARTERED ACCOUNTANTS

B. V. RAMANA REDDY
M. No: 026967 Partner

Place: Hyderabad
Date: 12.02.2025
UDIN: 25026967BMMLSD9920

E-mail : mateshca@yahoo.co.in
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN:L24110TG1986PLC006885

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.12.24

Rupees In Lakhs

S No	Particulars	Quarter Ended				Nine Months Ended		Previous Year Ended
		31.12.2024	30.09.2024	30.06.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	a) Net Sales / Income from Operations	3.35	5.48	20.86	13.61	29.69	196.67	211.15
2	b) Other Operating Income	0.00	-0.23	0.26	0.07	0.03	0.92	17.34
3	Total Income (1+2)	**3.35**	**5.25**	**21.12**	**13.68**	**29.72**	**197.59**	**228.49**
4	Expenditure							
	a) Cost of Material Consumed	3.15	1.46	11.93	119.75	16.54	224.88	233.15
	b) Employee Benefits Expenses	4.29	3.47	4.09	6.19	11.85	47.47	56.21
	c) Changes in inventory	0.03	5.31	-1.31	126.09	4.03	130.55	138.37
	d) Finance cost	-1.46	1.70	0.01	14.13	0.25	40.59	48.20
	e) Depreciation	0.21	0.48	0.48	6.28	1.17	18.02	22.84
	f) Other Expenditure	9.19	40.19	16.05	21.86	65.43	125.68	437.13
	Total Expenses	**15.41**	**52.61**	**31.25**	**294.31**	**99.27**	**587.20**	**935.90**
5	Profit / (Loss) before Exceptional Items and tax (3-4)	**-12.06**	**-47.36**	**-10.13**	**-280.63**	**-69.55**	**-389.61**	**-707.41**
6	Exceptional Items	**-1.92**	**0.00**	**0.00**	**0.11**	**-1.92**	**0.11**	**0.11**
7	Profit / (Loss) before tax (5-6)	**-10.14**	**-47.36**	**-10.13**	**-280.74**	**-67.63**	**-389.72**	**-707.52**
8	Tax Expense							
	a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	129.40
	b) Deferred Tax	0.55	-0.12	0.17	-1.56	0.60	-0.10	-32.82
9	Profit / (Loss) after tax for the period from continuing operations (7-8)	**-10.69**	**-47.24**	**-10.30**	**-279.18**	**-68.23**	**-389.62**	**-804.10**
10	**Other comprehensive income**							
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		0.00	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	**-10.69**	**-47.24**	**-10.30**	**-279.18**	**-68.23**	**-389.62**	**-804.10**
12	Paid-up equity share capital	**813.14**	**813.14**	**813.14**	**813.14**	**813.14**	**813.14**	**813.14**
	(Face value of Rs. 10/- per share)							
13	**Other Equity**							-530.75
14	Earinings Per Share (EPS)							
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	-0.13	-0.58	-0.13	-3.43	-0.84	-4.79	-9.89
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	-0.13	-0.58	-0.13	-3.43	-0.84	-4.79	-9.89

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email:info@ortinlabsindia.com Website:www.ortinlabsindia.com
Ph. No. +91 9052011118

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN:L24110TG1986PLC006885

Notes:

(i) The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12th Febraury, 2025.

(ii) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules. 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.

(iii) The figures for the quarter ended December 31, 2024 and December 31, 2023 are balancing figures between the unaudited figures in respect of the first quarter, second quarter and year to date figures upto the third quarter for the respective period which were subject to limited review.

(iv) Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.

(v) The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.

(vi) The Statutory Auditors of the Company have carried out "Reveiw" of the above un-audited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

(vii) The results are also available on the website of the Company www.ortinlabsindia.com.

Place: Hyderabad
Date: 12.02.2025

For and on Behalf of the Board of Directors
ORTIN GLOBAL LIMITED

S.MURALI KRISHNA MURTHY
Managing Director
DIN: 00540632

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email:info@ortinlabsindia.com **Website:www.ortinlabsindia.com**
Ph. No. +91 9052011118

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE QUALIFIED INSTITUTIONS PLACEMENT ETC. - Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES - Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable.